TYPTF (Tryptamine Therapeutics) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Tryptamine Therapeutics Days Payable?

Tryptamine Therapeutics's average Accounts Payable for the six months ended in Dec. 2023 was $0.12 Mil. Tryptamine Therapeutics's Cost of Goods Sold for the six months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for Tryptamine Therapeutics's Days Payable or its related term are showing as below:

TYPTF's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 127.14
* Ranked among companies with meaningful Days Payable only.

Tryptamine Therapeutics's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Tryptamine Therapeutics Days Payable Historical Data

The historical data trend for Tryptamine Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Days Payable Chart

Tryptamine Therapeutics Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Days Payable

Get a 7-Day Free Trial

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Payable	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of Tryptamine Therapeutics's Days Payable

For the Biotechnology subindustry, Tryptamine Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tryptamine Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Tryptamine Therapeutics's Days Payable falls into.

Tryptamine Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Tryptamine Therapeutics's Days Payable for the fiscal year that ended in Jun. 2023 is calculated as

	Days Payable (A: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2022 )	+	Accounts Payable (A: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2023 )	*	Days in Period
=	( (0.15	+	0.026)	/	2 )	/	0	*	365
=	0.088					/	0	*	365
=	N/A

Tryptamine Therapeutics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0.026	+	0.21)	/	2 )	/	0	*	365 / 2
=	0.118					/	0	*	365 / 2
=	N/A

Tryptamine Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (OTCPK:TYPTF) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

TYP:Australia

Address

C/o Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124

Website

https://www.tryptherapeutics.com

Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Tryptamine Therapeutics Headlines

From GuruFocus

Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement

By PRNewswire PRNewswire • 01-31-2022

Exopharm Gains US Patent Enabling Commercial Production of Exosome Medicines

By PRNewswire PRNewswire • 12-22-2021